Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX-0171 in Japanese Infants with RSV LRTI
NCT03418571Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of gontivimab in respiratory syncytial virus infection (RSV), sponsored by Sanofi. Started Mar 2018; status: terminated.
02
Drugs
gontivimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03418571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03418571.